BioCentury
ARTICLE | Clinical News

Lomitapide regulatory update

May 7, 2012 7:00 AM UTC

FDA accepted for review an NDA from Aegerion for lomitapide to treat homozygous familial hypercholesterolemia (HoFH). The PDUFA date is Dec. 29. In March, FDA informed the company that the compound wo...